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Batten disease is a group fatal inherited neurodegenerative diseases typically manifesting in humans 
in childhood.  The diseases are genetically heterogeneous and characterised by cognitive loss, 
psychomotor deterioration, retinal degeneration, brain atrophy, seizures and premature death. 
Treatments for Batten disease are at an early stage, but this study is part of the development of 
gene therapy for the disease caused by mutations in CLN5 and CLN6. 
Many of the forms of Batten disease that occur in humans have also occurred spontaneously in large 
animals, including ovine species. Two naturally occurring sheep models of NCL are maintained at 
Lincoln University, a CLN6 form in South Hampshire sheep and a CLN5 form in Borderdale sheep. 
Affected sheep are normal at birth, but develop clinical symptoms at around 10-14 months of age. 
These include progressive loss of sight, and psychomotor decline, as a result of severe cortical loss 
and loss of retinal photoreceptors. Premature death generally occurs at around 2 years of age. 
Cognitive decline is a common symptom of human Batten disease and also occurs in the CLN5 and 
CLN6 ovine forms of the disease. The purpose of this study was to investigate if a closed-field maze 
test could be a useful method for determining loss of cognition in sheep with Batten disease. It was 
hypothesised that cognitive decline may affect an affected sheep’s ability to transit a mazes, hence 
offering a potential method for early diagnosis of the disease. This would help speed up the 
optimisation of therapeutic interventions, by providing an early measure of their efficacy.  
The study consisted of three experiments. The first experiment involved the development of a maze 
that was navigable by the sheep, and complex enough to discern between normal and affected 
animals. Time to complete, and path length, determined by high precision GPS, were both used as 
measures of the sheep’s ability. The second experiment used the final iteration of the maze 
 
 
developed in experiment one, to determine when differences could be seen between normal and 
affected animals, and measure the effectiveness of the gene therapy treatment. The final 
experiment used a more cognitively complex maze that used visual cues to indicate the correct path 
through the maze.  
This study established that sheep were able to navigate a complex maze. The performance of the 
normal cohort of both breeds was the same. All animals were slowest and took their longest paths 
when first exposed to the maze, but were faster and took shorter paths in subsequent transits. The 
untreated affected cohorts of both genotypes were generally slower and took a longer path length 
through the maze than their unaffected counterparts. The loss of ability of individual affected (both 
untreated and treated) animals to negotiate the maze correlated well with other measures of 
disease progression. Due to the very variable performance of affected and treated animals, the 
experiment did not achieve the objective of being able to discern the onset of Batten disease at an 
earlier stage than other measures currently in use. 
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1 Introduction 
Batten disease is a group of diseases referred to as neuronal ceroid lipofuscinoses (NCLs). This is a 
group of fatal inherited neurodegenerative diseases typically manifesting in humans in childhood. 
The NCLs are classified as rare diseases, and thought to have an incidence of about 1:12,500 
births (Rider & Rider, 1988).  The diseases are genetically heterogeneous, with defects in any one 
of 13 genes, designated CLN1-8 and 10-14 that cause NCL. As a group, they are characterised by 
cognitive loss, psychomotor deterioration, retinal degeneration, brain atrophy, seizures and 
premature death (Mole, Williams, & Goebel, 2005). At a cellular level the diseases are 
characterised by a widespread accumulation of protein, either subunit c of mitochondrial ATP 
synthase or saponins A and D, in lysosome derived storage bodies (Palmer, 2015). Treatments for 
Batten disease are at an early stage, but this study is part of the development of gene therapy for 
the disease caused by mutations in CLN5 and CLN6. 
Many of the forms of Batten disease that occur in humans have also occurred spontaneously in 
large animals, including ovine, bovine, caprine, canine, equine, feline and porcine species (Bond, 
Holthaus, Tammen, Tear, & Russell, 2013). Affected sheep make useful models, as they 
demonstrate many of the clinical and pathological symptoms found in the human diseases. Their 
gyrencephalic brain is similar in organisation to the human brain, and is of a convenient size for 
potential therapies. Sheep are amenable to handling and can be kept at a low cost. Two naturally 
occurring sheep models of NCL are maintained at Lincoln University : a CLN6 form in South 
Hampshire sheep and a CLN5 form in Borderdale sheep (Jolly, Arthur, Kay, & Palmer, 2002; Jolly 
RD, 1975). Affected sheep are normal at birth, but develop clinical symptoms at around 10-14 
months of age. These include progressive loss of sight, and psychomotor decline, as a result of 
severe cortical loss and loss of retinal photoreceptors. Premature death generally occurs at 
around 2 years of age. 
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All different forms of Batten disease stem from the loss of gene function, therefore gene therapy 
would appear to be a promising form of treatment of the disease. In this study self-
complementary adeno-associated viral vectors (scAAV) were used to deliver a normal functional 
copy of the CLN5 and CLN6 Batten disease genes. Treatment efficacy can be judged by 
longitudinal neuroimaging to measure brain atrophy, and clinical scoring using Batten disease 
rating scales to measure cognitive, vision and motor decline. Human  assessment methods have 
been adapted for use in ovine forms of the disease (Mitchell et al., 2018; K. N. Russell et al., 
2018).  
The current studies in the ovine forms of CLN5 and CLN6 Batten disease are using longitudinal 
computed tomography (CT) imaging to measure any decline in intracranial volumes as an 
indicator of brain atrophy, electroretinography (ERG) to measure retinal degeneration, and a 
range of assessments included in the ovine Batten disease rating scale (oBDRS). The oBDRS 
consists of physical assessments of visual and auditory function, posture, movement, body 
tremors and body condition scoring, as well as behavioural assessments of mentation, aggression 
and capability/independence (Mitchell et al., 2018).  
Cognitive decline is a common symptom of human Batten disease (Anderson, Goebel, & 
Simonati, 2013) and also occurs in the CLN5 and CLN6 ovine forms of the disease (Mitchell 2018, 
2019). The purpose of this study was to investigate if a closed-field maze test could be a useful 
method for determining loss of cognition in sheep with Batten disease. It was hypothesised that 
cognitive decline may affect an affected sheep’s ability to transit a mazes, hence offering a 
potential method for earlier diagnosis of the disease than is possible with current methods. This 
would help speed up the optimisation of therapeutic interventions, by providing an early 
measure of their efficacy. To this end untreated Batten diseased sheep, sheep with Batten 
disease undergoing gene therapy treatments, and healthy normal sheep were tested in a variety 
of mazes. Some of the animals used were involved in other studies, hence underwent concurrent 
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computed tomography scanning and electroretinography to monitor brain atrophy and retinal 
function respectively, and a range of other non-invasive tests to assess their disease progression. 
1.1.1 History of the field maze and the two choice maze 
The use of a closed field maze to test the ‘mental’ ability of rats was first published in 1946 (Hebb 
DO, 1946). This field maze consisted of a square arena with an entrance in one corner and food 
reward in the opposite corner. The path between the corners was obstructed by panels to create 
a maze, and the animal was scored on the number of times it entered error zones. Twelve 
different formats of the maze were used to test each animal. This maze was modified ( Figure 
1-1) (Rabinovitch, MS., 1951) and divided into 36 squares and this formed the grid pattern for the 
placement of the barriers. A set of 6 relatively simple training problems was developed, and a 
further set of 12 more complex test mazes.  The Hebb-Williams maze is still being used today and 
has been used to test rats, cats, rabbits, ferrets, possum, mice, voles, sheep, rams, lambs, 
goldfish, leghorn chicks, bears, raccoons, baby monkeys, cows and even humans (Shore, Stanford, 
MacInnes, Brown, & Klein, 2001). This form of maze is primarily designed to measure spatial 
memory and learning. 
 
Figure 1-1. The six acquisition mazes (A-F), and 12 testing mazes in the Hebb-Williams maze as 
modified by Rabinovitch (1951). 
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The first records of the Hebbs–Williams maze in use with large animals were with sheep (Kilgour, 
R.; Bruere, 1970) and dairy cows (Kilgour, 1981). The majority of work with such a maze has been 
in rats, and scaled up versions have been used to  test sheep (Lee, Colegate, & Fisher, 2006), 
cattle (Hirata, Tomita, & Yamada, 2016; Kilgour, 1981), pigs (Jansen, Bolhuis, Schouten, Spruijt, & 
Wiegant, 2009) and dogs (Elliot & Scott, 1965). The experimental use of mazes has revealed that 
sheep and other large herbivores have excellent spatial cognition and memory. It is thought that, 
as animals that would naturally graze over extensive areas, this ability has allowed them to return 
to particular food sources repeatedly over time (Dumont & Petit, 1998; Edwards, Newman, 
Parsons, & Krebs, 1997).  The ability to traverse a maze has been studied with sheep subjected to 
negative stimuli such as images of dogs or white noise (Doyle, Freire, Cowling, Knott, & Lee, 
2014).  As testing of large animals in mazes has increased, the recognition of their capabilities has 
become apparent, their usefulness as models of many diseases has also been realised. 
The two choice maze was also investigated in this study. In this maze, the animal has a choice 
between two paths; the correct path leading to a food reward, or passage through the maze. This 
form of maze is generally accepted to have originated in the USA in the 1890s, for use with rats. 
Rodents, particularly rats, are still the main subject for this type of maze, but it is now more 
commonly being used in large animal studies. Examples include studying learning, cognition, drug 
effects, and mental states. These mazes are generally in the form of a T shape (Camm, Gibbs, 
Cock, Rees, & Harding, 2000; Johnson, Stanton, Goodlett, & Cudd, 2012; Taylor, Brown, Price, & 
Hinch, 2010) or a Y (Ferreira, Keller, Saint-Dizier, Perrin, & Lévy, 2004; Hernandez et al., 2009; 
Hunter et al., 2015; Kendrick et al., 1995; Peirce, Leigh, Dacosta, & Kendrick, 2001) , giving a two 
choice option. This format is useful to test the ability of an animal to learn to associate symbols, 
colours or pictures with food rewards or passage through the maze. The ability of sheep to learn 
these associations, and then learn reversal of the association has been tested thoroughly (Hunter 
et al., 2015; Johnson et al., 2012; McBride, Perentos, & Morton, 2016; Morton & Avanzo, 2011; 
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Taylor et al., 2010). This ability has been tested when animals that have been exposed to 
intrauterine undernutrition (Camm et al., 2000; Erhard, Boissy, Rae, & Rhind, 2004; Hernandez et 
al., 2009), and used to study foraging strategies (Hosoi, Swift, Rittenhouse, & Richards, 1995).  
Our understanding of the cognitive capacities of sheep has increased enormously in the last few 
years.  The increased use of large animal models in medical research, and an increased awareness 
of animal welfare has caused an increase in studies into cognition and learning abilities. It is 
becoming increasingly obvious that the public perception that domesticated ungulates are 
“stupid” is misplaced. Through the use of mazes we now know that they are capable of 
recognition of colours, symbols and faces, both of their own species and humans. Once learned 
we know that the animals can reverse their learning, or shift their learning from one dimension to 
another i.e. learning a coloured bucket, then shifting to the same coloured cone. We also know 
that once learned, sheep can retain this knowledge for long periods of time, up to at least 2 years 
in the case of recognition of human faces (Keith, Ana, Andrea, Michael, & Jon, 2001). Cognitive 
tests for use on sheep have become more and more sophisticated as the ability of the sheep is 
better understood. One group of researchers (McBride et al., 2016) have developed a semi-
automated mobile system that has LCD screens to display symbols, and an automatic food 
reward dispenser that dispenses food when the animal approaches the correct screen. This 
system has then been used to trial stop signals (Knolle, McBride, Stewart, Goncalves, & Morton, 
2017) and stop signal reaction time. The work demonstrated that sheep are able to negotiate a 
two choice maze, a complex cognitive task, and are able to stop the response 91% of the time. 
The drawback to this level of complexity is the time taken to conduct the trials. The study of the 
stop signal task (Knolle et al., 2017)  required about 300 runs/animal of training, and 450 runs for 
the experiment. These were animals that had also historically been used in other cognition trials 
by the same group (McBride et al., 2016; Morton & Avanzo, 2011), so were somewhat 
conditioned to this form of experiment before they started. 
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Despite this knowledge of the cognitive capabilities of animals, studies that use these testing 
systems in an applied way are limited. As previously described, mazes have been used in a few 
studies on sheep on the effects of prenatal undernutrition, and also the effect of stressors such 
as dogs or white noise. There do not appear to be any studies using maze ability to measure 
disease progression in sheep.   A T-maze has been used to study cognitive decline in a dog model 
of CLN2 Batten disease (Sanders et al., 2011), and was found a significant difference between 
normal and affected animals at an earlier stage than any other clinical indicators the researchers 
were using.   
In the current study we started with a simple field maze, in a rectangular format, with a series of 
gates to be negotiated for the animal to get to conspecifics housed at the far end. The maze was 
developed during the course of the study to increase its complexity whilst retaining its 
practicality.  
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2 Development of a closed-field maze 
2.1 Materials and methods 
2.1.1 Animals and experimental design 
This maze study was conducted on 22 animals in accordance with the NZ Animal Welfare Act 
(1999) and approved by the Lincoln University Animal Ethics Committee (LUAEC #614). All trial 
sheep were first tested at 8.5 months of age (range min 7.6, and max 8.9) in four different 
cohorts  
The normal control cohort consisted of three South Hampshire CLN6+/- and three Borderdale 
CLN5+/- sheep. The affected cohort consisted of three South Hampshire CLN6-/- and three 
Borderdale CLN5-/- sheep. The first treated cohort consisted of six South Hampshire CLN6-/- sheep 
who received intracerebroventricular delivery of either scAAV9.CLN5 or scAAV9.CLN6 at 3 
months of age. The second treated cohort consisted of four Borderdale CLN5-/- sheep who 
received intracerebroventricular delivery of scAAV9.CLN5 at 7 months of age. All 22 animals were 
part of other projects within the Batten disease research project and hence received CT scans and 
electroretinography every 2-3 months throughout their lifetime (Mitchell et al., 2018; K. N. 
Russell et al., 2018).  Animals were grazed on grass/white clover pasture with water available ad 
libitum. 
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Sheep 
# 
Genotype Treatment Other in vivo assessments 
1001 CLN6+/- 
None, normal 
control 
 
 
 
CT, ERG (Russell 2017, Russell et 
al., 2018) 
1004 CLN6+/- 
1005 CLN6+/- 
1100 CLN5+/- 
1105 CLN5+/- 
1106 CLN5+/- 
1008 CLN6-/-   
None, affected 
control 
CT, ERG (Russell 2017, Russell et 
al., 2018) 
1014 CLN6-/-   
1109 CLN5-/-   
1110 CLN5-/-   
1122 CLN5-/-   
1033 CLN6-/-   scAAV9.CLN5@ 3 
months  
CT, ERG 
 
1040 CLN6-/-   
1038 CLN6-/-   scAAV9.CLN6@ 3 
months 
 
1042 CLN6-/-   
1045 CLN6-/-   
1164 CLN5-/- 
scAAV9.CLN5 @ 7 
months 
 
CT, ERG (Mitchell et al., 2018) 
 
1165 CLN5-/- 
1170 CLN5-/- 
1172 CLN5-/- 
Table 2-1. List of animals used in Experiment 1. 
 
2.1.2 Maze 
A simple closed field maze was utilised at approximately monthly intervals to assess the visual 
and cognitive faculties of normal (heterozygous), affected, and affected sheep of both genotypes 
that had received gene therapies. It was constructed in a 5.8m wide lane between two 5 wire 
fences. The ends of the maze, and all internal dividers were tubular metal gates with wire mesh 
infills which allowed uninterrupted sight for each individual test subject through the maze to 
conspecifics housed in an end pen (Figure 2-1). When an animal was released from the holding 
pen, it was subject to two drivers that made it traverse the maze, the desire to get away from the 
operator, and the desire to be reunited with its conspecifics. Each animal was tested in a 
sequence of either 4 or 5 consecutive runs.  
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Figure 2-1. Layout of first three mazes.  
 
The configuration of the maze was adapted over the course of the study. The initial maze 
consisted of a series of three gates over a distance of 26.6 metres (Figure 2-1 A), and the animals 
were first tested at a mean age of 8.5 months. The final maze alteration was made when the 
animals were tested at 16 months of age (Figure 2-2). An extra gate to negotiate was included, 
with an extra error space, and the maze was shortened by 5 metres to bring the conspecifics 
closer, presenting a stronger draw for the test animal. This also brought the conspecifics out of 
the shade of a wooded shelter belt, and hence they were more visible to the test animal. The 
position of the operator did not change during any of these maze iterations, and the ground was 
sprayed with glyphosate when required to keep it free of plant material which could be a 
distraction for the sheep. 
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Figure 2-2. Final maze layout for Experiment 1. 
2.1.3 GPS tracking 
 Figure 2-3. Animal with GPS tracker unit attached. 
 
Animals wore a simple Velcro (50mm wide) home–made harness during testing, consisting of a 
neck and chest strap ( Figure 2-3). A GPS tracker (Trimble R1, Trimble Inc, Sunnyvale, CA.) was 
attached to this, set to record at a frequency of 1Hz. It was operated via a Bluetooth connection 
to a laptop located beside the operator at the start of the maze. Data was processed by Trimble 
Terrasync Software (v5.90), and then sent to AllTerra NZ (Addington, Christchurch, NZ), for 
centimetre level post-processing. Each test subject was held in the start pen whilst the GPS 
software was initiated before the start of each maze run, and then for a further 15 seconds to 
allow the starting point to be identified in the GPS data (the first recording where either the 
Easting or Northing position moved by more than 20cm).  
20.6m 
5.8m 
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 To back up the GPS data the time taken from exiting the start pen, to passing the final gate, was 
also recorded manually with a stopwatch by the operator. The cut off point for the time was 20m 
through the maze in the first 3 maze iterations, when it was 25m long. The final maze was only 
20m long and the cut-off point was 15m, or when the animal passed the last gate. Animals were 
allowed 120 seconds to complete the maze, otherwise they were judged to have failed. When 
that happened they were pushed through by the operator, and given a recorded time of 120 secs. 
Each maze test session initially comprised of 4 runs, but from 9.4 months of age (min 8.5, max 
9.8) all animals were tested over 5 runs. Average times for the 4-5 runs were reported, with 
animals failing all 4-5 runs given an average time of 120 secs. All animals were tested in blocks at 
approximately monthly intervals. 
2.1.4 Gene therapy 
The gene therapy treatment involved intracerebroventricular delivery of a gene therapy vector, 
self-complementary adeno-associated virus serotype 9 (scAAV9) expressing either the ovine CLN5 
or CLN6 genes. In brief, under stereotaxic guidance, a total volume of 400 μl of vector was 
injected into each cerebral lateral ventricle (Mitchell et al., 2018). The first treated cohort 
consisted of four Borderdale CLN5-/- sheep who received 4.0 x 1012 vg (viral genomes) of 
scAAV9.CLN5 at 7 months of age.  Six South Hampshire CLN6-/- sheep in the second cohort 
received either 4.6 x 1012 vg of scAAV9.CLN5 (n=3) or 3.5 x 1012 vg of scAAV9.CLN6 (n=3) at 3 
months of age.  
2.1.5 Electroretinography (ERG) 
All animals involved in this trial also received two monthly electroretinography as part of a 
separate trial to test retinal function (K. Russell, 2017). This was conducted using an Eickemeyer 
Veterinary ERG system (Eickemeyer -Medizintechnik für Tierärzte KG, Tuttlingen, Germany) and 
measured the action potential generated by the retina in response to a flash of light. 
12 
 
Measurements were conducted under conditions of ambient light, in the dark (dark adapted), 
and after being in the dark for five minutes (5 mins dark adaption). The amplitude data for the 5 
mins dark adapted a and b waves were then compared to the maze traverse times for these 
animals.  
2.1.6 Intracranial volume (ICV) 
Intracranial volume has been  proven as an accurate surrogate for brain volume in ovine NCL (K. 
N. Russell et al., 2018). Intracranial volume data were collected for all animals in the present 
study as part of other concurrent trials (Mitchell et al., 2018; K. N. Russell et al., 2018). Volume 
measurements were inferred from three-dimensional reconstructions of the cranium from 
longitudinal computed tomography (CT) scans by established methods (K. Russell, 2017). 
2.1.7 Statistical techniques 
Means and corresponding SEM was calculated for each group at each time point. Student’s t-
tests were performed to test each group against the normal controls at each time point. 
Differences were regarded as significant where P<0.05. Where individual treated and untreated 
affected animals were compared to the control group, they were considered to be significantly 
different from controls when they were more than 1.96 standard deviations away from normal 
control mean values. 
2.2 Results 
2.2.1 Heterozygous normal control animals 
Mean traverse times for heterozygous normal control sheep of each breed were plotted (Figure 
2-4). Times were not significantly different (P>0.05) for the unaffected CLN5+/- and CLN6+/- control 
groups at any time over the whole experiment, but there was a trend for the Borderdale CLN5+/- 
to be slower than the South Hampshire CLN6+/-. More variation was observed in the traverse 
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times of the CLN5+/- cohort, who would often stop and stand still towards the end of maze. In 
comparison the CLN6+/- sheep exhibited a stronger desire to get away from the operator, and 
associate with conspecifics. 
Over the course of the experiment the traverse times for the CLN6+/- cohort gradually slowed 
(Figure 2-4), and were significantly (P<0.05) slower from 14 months onwards than they were at 
the start of the experiment. The more variable CLN5+/- cohort showed no significant change in 
traverse times over the course of the experiment. 
 
 
Figure 2-4. Mean (+/- sem) maze traverse times for normal CLN5+/- and CLN6+/- cohorts. 
Whilst the path through the maze taken by individual animals within the two control cohorts did 
not vary significantly (P>0.05), their times between 9-13 months of age frequently did. Figure 2-5 
shows the spatial paths of a normal control CLN5+/- and CLN6+/- animal at 13 months of age. 
Although the path is very similar, the average time taken by the CLN5+/- animal was significantly 
longer (P<0.05, mean time of 65s for the CLN5+/- vs 8.9s for the CLN6+/-).  
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Figure 2-5.Representative spatial plots (collected at 1Hz) of five traverses through the maze by  13 
month old normal control CLN5+/- and CLN6+/- animals. The CLN5+/- sheep recorded a mean 
traverse time of 65 seconds and the CLN6+/- animal a mean time of 8.9 seconds.  
2.2.2 Maze traverse times of the normal control and affected cohorts 
The mean traverse time for CLN5-/- affected sheep was very similar to the CLN5+/- normal animals, 
until around 16 months of age (Figure 2-6). After that the affected cohort times slowed, although 
statistical significance was not achieved as comparative data for the normal cohort ended at 17.5 
months when these animals returned to the heterozygous breeding flock. All CLN5-/- affected 
animals failed to negotiate the maze before or at 19.5months.  
The pair of affected CLN6-/- sheep were significantly (P<0.05) slower than the normal CLN6+/- 
animals in traversing the maze from 11 months old. One of the CLN6-/- sheep could no longer 
traverse at 14 months, and the other CLN6-/- sheep failed to complete the maze at 16.3 months 
(Figure 2-6). 
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Figure 2-6. Mean (+/- sem) maze traverse times for normal (blue line) and affected (red line) 
CLN5 and CLN6 cohorts. All cohorts n=3 except CLN6-/- n=2. Asterisk denotes significant 
difference (P<0.05). 
2.2.3 Comparison of maze distance ratios for control and affected cohorts 
It was noted that the Borderdale CLN5 sheep had behavioural differences to the South 
Hampshire CLN6, they appeared more habituated to humans, and had less attraction to their 
cohort. They would often stop in the middle of the maze, and watch the operator, rather than 
continue to their conspecifics at the end of the maze. This trait resulted in slow times, despite 
them having no difficulty in traversing the maze.  To remove time spent stationary from the 
assessment, the GPS track data were used to calculate the distance the animals walked as a 
proportion of the linear distance through the maze. Figure 2-7 illustrates the GPS tracks over 5 
attempts for two animals. The CLN5+/- takes a very direct path through the maze on each 
attempt, whilst the CLN6-/- animal made several mistakes. Analysis done on a time basis ( 
Table 2-2), showed that the CLN6-/- animal had a faster time (mean 50.5s) than the CLN5+/- 
sheep mean 93.4s) despite the errors made by the former. In comparison, analysis of the distance 
travelled as a proportion of the linear distance ( 
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Table 2-2), revealed that the CLN6-/- animal had a higher ratio of distance travelled (1.6 vs 1.38), 
more accurately reflecting its poorer ability to traverse the maze.
 
Figure 2-7. Spatial GPS plots (collected at 1Hz) of five traverses through the maze by a single 
CLN5+/- and CLN6-/- animal. 
 
 CLN6-/- CLN5+/- 
Run Time (s) Dist (travelled/linear d.) Time (s) Dist (travelled/linear d.) 
1 34.2 1.50 54.0 1.35 
2 19.8 1.32 120.0 1.35 
3 18.8 1.30 90.8 1.38 
4 120 1.95 120.0 1.35 
5 59.2 1.76 82.2 1.48 
mean 50.4 1.6 93.4 1.38 
 
Table 2-2. Time to traverse and distance travelled as a proportion of linear distance through the 
maze. Data from five runs from two animals as illustrated in Figure 2-7.  
 
The distance travelled as a proportion of the linear distance was calculated for all four cohorts 
(Figure 2-8) and showed that contrary to the time results (Figure 2-6), the variability in the data 
was greatly reduced. The CLN5-/- sheep went significantly (p<0.05) further than their normal 
CLN5+/- counterparts at the 8.5 and 14 months. The CLN6-/- sheep did not travel significantly 
(P>0.05) further at the 8.5 or 9 month time points, but did when 11 months, and at all remaining 
ages.   
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Figure 2-8. Mean (+/- sem) ratio of distance travelled by the animals as a proportion of the 
linear distance through the maze for normal (blue line) and affected (red line) CLN5 and CLN6 
cohorts. All cohort n=3 except CLN6-/- n=2. Asterisk denotes significant difference (P<0.05). 
2.2.1 Comparison of maze traverse times and electroretinogram responses for control and 
affected cohorts 
Electroretinography showed that the dark adapted a and b-waves declined steadily for both 
CLN5-/- and CLN6-/- animals (Figure 2-9) from around 2 months of age. The ability to traverse the 
maze persisted even with major declines in eyesight, but as the amplitude of the a and b waves 
approached zero, indicating retinal blindness, then the animals failed to traverse the maze.  
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Figure 2-9. Comparison of maze traverse times (red line, primary y-axis), dark adapted a-wave 
electroretinogram (grey line, secondary y-axis), and dark adapted b-wave (yellow line, secondary 
y-axis). Data from two typical CLN5-/- and CLN6-/- animals. 
2.2.2 Comparison of maze traverse times and intracranial volume for control and affected 
cohorts 
The ICV was compared to maze traverse times (Figure 2-10), in untreated animals of both 
genotypes. The cranial volume declined earlier than the maze traverse times. In both the CLN5 
and CLN6 genotypes, the ICV were starting to decline at around 6 months of age, well before 
there was a slowing in maze traverse times.   
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Figure 2-10. Representative data from two CLN5-/- and two CLN6-/- animals, showing maze 
traverse times (red line, primary y-axis), and intracranial volume change (orange line, secondary 
y-axis).  
2.2.3 Comparison of traverse times for the CLN5-/- treated cohort  
Maze traverse times for the four CLN5-/- animals who received brain-directed scAAV9.CLN5 gene 
therapy at 7 months were plotted against the mean normal and untreated CLN5-/- sheep data. 
Results are presented in Figure 2-11 and Table 2-3.  
The treated and untreated CLN5-/- cohorts did not become significantly (95% c.i.) slower than 
their normal counterparts until 14 months of age (Table 2-3). One of the four treated animals 
(165) followed a similar trajectory in maze function to the untreated CLN5-/- sheep, failing to 
traverse at 19.4 months. The remaining three treated animals kept traversing until 22.9 months 
(1164) and 24.1 months (1172 and 1170).   
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Figure 2-11. Mean (+/- sem) maze traverse times for normal and affected CLN5 cohorts, with 
times for four individual CLN5-/- animals treated by gene therapy at 7 months of age. 
 
 Age (months) 
Tag# 8.5 9.5 11 12 13.2 14 16.3 17.5 18.3 19.6 20.4 21.4 22.9 24.1 
Untreated CLN5-/- 
1122 14.4 15.8 16.6 12.5 18.4 16.5 39.5 67.6 120      
1110 30.3 27.7 29.2 14.7 19.8 74.2 16.7 43.7 120      
1109 11.8 21.7 24.9 23.7 15.7 71 30.8 19.8 17.3 120     
Treated at 7 months of age CLN5-/- 
1164 9 11.7 14 9.9 11.4 28.4 17.4 18.3 33.7 35.56 89.54 100.8 120  
1165 11 12.2 15 18.7 13.6 38.8 110.8 87.4 102.6 120     
1170 13 24.7 24.1 22.1 30.5 36.2 32.9 40.9 52.3 113 74.8 72.9 65.6 101.4 
1172 10 21 18.3 14.7 18.6 59.4 23.6 45 54.3 55.4 63.6 87.6 63.8  
Table 2-3.Mean traverse times for individual untreated and treated CLN5-/- animals. Red figures 
indicate significantly slower (95% c.i.) than the normal control group (control group data ends at 
17.5 months). 
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2.2.4 Comparison of maze distance ratios for the CLN5-/- treated cohort  
The ratio of distance travelled to linear distance for the CLN5-/- animals who received brain-
directed scAAV9.CLN5 gene therapy at 7 months was plotted against the mean normal and 
untreated CLN5-/- sheep data (Figure 2-12 and Table 2-4). The distance ratio of untreated animals 
was not significantly different (p<0.05) to normal controls up to 14 months of age. By 14 months 
of age all untreated and treated animals were taking a significantly (P<0.05) longer route 
 
Figure 2-12. Mean (+/- sem) ratios of distance travelled to linear distance through the maze  
for normal and affected CLN5 cohorts, with ratios for four individual CLN5-/- animals treated by 
gene therapy at 7 months of age. 
 
through the maze. Individual variations were apparent. Treated animal 1165 did not respond as 
robustly to the treatment. It was significantly slower (95% c.i.) than normal animals from 11 
months and failed to complete the maze at 19.6 months. In comparison , treated animals 1164 
and 1172 were not significantly (P<0.05) different from normal controls when last tested at 17.5 
months of age, but gradually deteriorated and lost the ability to traverse at 22.9 months. Animal 
1170 was also taking a much longer route, but was still able to traverse at 24.1 months. 
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 Age (months) 
Tag# 8.5 9.5 11 12 13.2 14 16.3 17.5 18.3 19.6 20.4 21.4 22.9 24.1 
Untreated CLN5-/- 
1122 1.32 1.30 1.31 1.32 1.39 3.63 2.24 3.32 F      
1110 1.30 1.30 1.39 1.31 1.29 3.30 1.48 1.78 F      
1109 1.22 1.34 1.52 1.30 1.29 5.30 3.17 1.60 1.52 F     
Treated at 7 months of age CLN5-/- 
1164 1.31 1.33 1.38 1.47 1.27 3.48 1.95 1.70 1.97 2.08 2.74 2.68 4.28  
1165 1.27 1.29 1.48 1.51 1.98 4.51 7.32 4.84 4.35 F     
1170 1.3 1.80 1.38 1.35 1.36 2.95 1.98 2.17 1.91 1.66 1.50 1.64 1.77 2.45 
1172 1.18 1.34 1.27 1.27 1.24 2.94 1.61 1.69 1.73 1.62 2.00 N/D 2.48 F 
Table 2-4. Mean individual ratios of distance travelled to linear distance through the maze, for 
affected and CLN5-/- treated by gene therapy at 7 months of age. Red figures indicate significantly 
slower (95% c.i.) than normal control group (control group data ends at 17.5 months). 
2.2.5 Comparison of maze and ERG findings for the CLN5-/- treated cohort 
ERG recordings were being taken every two months on these normal, untreated and treated 
CLN5 animals as part of concurrent trails. Russell (K. Russell, 2017) had demonstrated the 
diminution of dark adapted a and b wave amplitudes in untreated CLN5-/- sheep over time. By 18 
months their ERG traces were largely flat line. The treated sheep also lost their ERG responses, 
but this was delayed in most. In this trial the poorest performing treated animal (1165) (Figure 
2-13), was also the first to lose its ERG response, and by 16 months it was a flat line. The two 
animals that were the best at traversing the maze at 22.9 months, also that had the best ERG 
responses (Figure 2-13) at 22 months.   
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Figure 2-13. ERG responses of the four treated CLN5-/- sheep at 8, 16 and 22 months. 
A summary of the clinical data, ERG responses and intracranial volume changes recorded in the 
concurrent study on the CLN5-/- untreated and treated sheep is presented in Table 2-5. 
Animal Genotype Treatment Failure 
in maze  
Minimal 
ERG  
ICV 
changes 
over time 
Clinical outcome 
1122 CLN5-/- None 18.3 17.8 -10.5 mL  
(3 – 18 m) 
Euthanised at 18.3 m, 
blind, advanced disease 
1109 CLN5-/- None 19.6 18 -12.9 mL  
(3 – 23 m) 
Euthanised at 23.1m, 
blind, advanced disease 
1110 CLN5-/- None 18.3 18 -10.9 mL  
(3 – 19 m) 
Euthanised at 19.6m, 
blind, advanced disease 
1164 CLN5-/- scAAV9.CLN5 
at 7m 
22.9 20.2 -1.2 mL 
 (7 – 44 m) 
Alive at 44 m, blind, 
mild clinical disease 
1165 CLN5-/- scAAV9.CLN5 
at 7m 
19.4 14.2 -4.2 mL  
(7 – 22m) 
Euthanised at 22.5 m, 
blind, moderate clinical 
disease 
1170 CLN5-/- scAAV9.CLN5 
at 7m 
> 24.1 22.3 +2.4 mL  
(7 – 42 m) 
Euthanised at 42.4 m, 
blind, moderate clinical 
disease 
1172 CLN5-/- scAAV9.CLN5 
at 7m 
22.9 20.5 -0.6 mL 
 (7 – 22 m) 
Euthanised at 22.3 m, 
visual deficits, mild 
clinical disease  
Table 2-5. Summary of data collected on untreated and treated CLN5-/- animlas. NB. 1172 was 
euthanised as a comparative neuropathological control for 1165, not because of its clinical status. 
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The untreated CLN5-/- animal (1109) that was able to traverse the maze for longest was also the 
animal that survived the longest. The treated animal (1165) that failed to traverse the maze the 
first was also the animal that lost the most ICV volume and the first of the treated cohort to lose 
an ERG response. The only treated animal that failed to lose any ICV volume (1170) was the 
animal that was able to traverse the maze the longest. 
2.2.6 Comparison of traverse times for the CLN6-/- treated cohort 
Maze traverse times for five CLN6-/- animals who received brain-directed scAAV9.CLN5 or CLN6 
gene therapy at 3 months were plotted against the normal and untreated CLN6-/- sheep data. 
Results are presented in Figure 2-14 and Table 2-6. 
Figure 2-14Mean (+/- sem) maze traverse times for normal and affected CLN6 cohorts, with 
times for five individual CLN6-/- animals treated by gene therapy at 3 months of age. 
The two animals in the untreated CLN6-/- cohort were significantly (P<0.05) slower than the 
untreated controls from when first tested at 8.5 months, and for the duration of the experiment 
(Table 2-6). The traverse times of the five CLN6-/- animals that had undergone gene therapy also 
slowed, but in general their loss of ability was delayed compared to the untreated CLN6-/- sheep 
(Figure 2-14). The treated CLN6-/- animals were all able to traverse the maze for longer than the 
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untreated affected cohort. Animal 1042 proved to be particularly capable, being able to traverse 
the maze until 22.9 months of age. 
 Age (months) 
 8.5 9.5 11 12 13.2 14 16.3 17.5 18.3 19.6 20.4 21.4 22.9 24.1 
Tag# Untreated CLN6-/- 
1008 12.8 67.5 25.9 24.7 46.8 120         
1014 11.9 14.8 18.8 20.5 22.8 66.8 120        
Treated CLN6-/- 
1033 6.5 11.9 12.7 10.5 8.7 67.6 64.7 108 120      
1038 7.2 11.3 14.1 11.7 17.1 35.1 76.6 120       
1040 12.6 10.0 8.4 8.1 21.8 39.0 57.1 75.4 99.4 120     
1042 48.8 12.8 27.5 18.0 38.8 120 37.9 16.2 58.7 22.0 58.5 99.2 120  
1045 9.0 12.8 24.7 15.8 16.8 20.8 36.5 120       
 
Table 2-6. Mean traverse times for individual untreated and treated CLN6-/- animals. Red 
figures indicate significantly slower (95% c.i.) than normal control group (control group data 
ends at 17.5 months). 
2.2.7 Comparison of maze distance ratios for the CLN6-/- treated cohort  
The ratio of distance travelled to linear distance for the CLN6-/- animals who received brain-
directed scAAV9.CLN5 or CLN6 gene therapy at 3 months was plotted against the CLN6-/- 
untreated and CLN6+/- normal controls (Figure 2-15 and Table 2-7). The distance travelled ratio 
showed all treated and untreated CLN6-/- animals taking a significantly (95% c.i.) longer route 
through the maze at 14 months of age. One of the affected controls (1008) travelled significantly 
(95% c.i.) further from 12 months of age, and failed to negotiate the maze at all at 14 months. 
Prior to that age there had been individual animals taking significantly (95% c.i.) longer routes at 
isolated time points.  The distance ratio data showed that treated animal 1042 followed a more 
direct route, similar to normal controls (Table 2-7), for most of the study, until failing to traverse 
at 22.9 months of age. 
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Figure 2-15. Mean (+/- sem) ratios of distance travelled to linear distance through the maze  
for normal and affected CLN6 cohorts, with ratios for five individual CLN6-/- animals treated by 
gene therapy at 3 months of age. 
 
Age (months) 
 8.5 9.5 11 12 13.2 14 16.3 17.5 18.3 19.6 20.4 21.4 22.9 24.1 
Tag# Untreated CLN6-/- 
1008 1.17 1.34 1.35 1.69 1.57 F         
1014 1.16 1.33 1.46 1.35 1.44 6.10 F        
Treated CLN6-/- 
1033 1.20 1.49 1.24 1.36 1.44 3.25 4.83 4.29 F      
1038 1.20 1.27 1.30 1.30 1.38 3.88 4.30 F       
1040 1.16 1.31 1.25 1.29 1.63 ND 3.00 5.24 9.53 F     
1042 1.25 1.25 1.29 1.31 1.26 4.93 1.78 1.40 1.75 1.55 2.41 ND F  
1045 1.18 1.27 1.30 1.35 1.32 2.30 2.71 F       
Table 2-7. Mean individual ratios of distance travelled to linear distance through the maze, for 
affected and  CLN6-/- sheep treated by gene therapy at 3 months of age. Red figures indicate 
significantly slower (95% c.i.) than normal control group (control group data ends at 17.5 months 
of age). ND = No data. 
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2.3 Discussion 
This study established that normal control and CLN5 and CLN6 affected sheep were able to 
navigate a long and complex maze. Sheep were enrolled at 8.5 months of age and several 
iterations of the maze were tested. The final version of the maze was not arrived at until the 
animals were 16 months of age but by then the maze had been developed into a quick and 
simple format that could be operated by a single person. Perhaps due to continued changes in 
the maze during its development, maze testing was not able to distinguish between healthy 
normal and affected animals at an earlier age than our other in vivo measures however it was a 
useful adjunct method to assess efficacy after CLN5 or CLN6 gene therapy. This study showed 
that the ability of affected animals to traverse the maze decreased as Batten disease progressed, 
and the gene therapy treatments allowed the animals to traverse for longer.  However although a 
good separation in maze traverse performance was achieved between the affected and normal 
cohorts, this also coincided with the severe deterioration of the eyesight of the affected and 
treated animals. This makes it difficult to fully attribute this loss of ability to traverse the maze to 
cognitive function.  
Time to traverse the maze was found to be very variable and not necessarily a good indicator of a 
sheep’s ability to traverse the maze. The two breeds of sheep behave very differently in the 
maze. The South Hampshires (CLN6) are of a more nervous disposition, and seem to acclimate to 
human contact slower than the Borderdales (CLN5). Hence the desire to get away from the 
operator, and through the maze appears to be more powerful in the South Hampshire as 
opposed to the Borderdales. The South Hampshire sheep also seems to have a stronger flocking 
instinct, so the attraction of flock-mates at the end of the maze is stronger. As an example at 13.2 
months the fastest Borderdale transited in 8.9seconds the slowest in 84.3 seconds which 
indicates the variability in fear of the operator and desire to return to conspecifics. Habituation to 
human contact has been described before in this type of testing scenario (Erhard, Elston, & 
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Davidson, 2006), and other researchers have also commented on the fact that Borderdale sheep 
would stop during passage through their maze test (McBride et al., 2016). Hence maze traverse 
time appears to be a good indicator of performance for the South Hampshire animals but not 
Borderdales.  
The use of the high precision GPS unit to calculate the path length through the maze significantly 
reduced the variability in the CLN5 Borderdale data, and allowed analyses such that animals 
stopping and standing did not influence the results. Thus distance ratios are a better indicator of 
performance for Borderdale sheep. 
Small numbers in cohorts, and high individual variability meant that statistical significance was 
often difficult to show, but at an individual level the maze results correlated well with other 
clinical observations. Of note, maze data showed a differential response to post-symptomatic 
scAAV9.CLN5 treatment. Three of the animals (1164, 1170 and 1172) responded well to 
treatment, they had stabilised brain volumes and were able to negotiate the maze up to 20.2, 
24.1, and 22.9 months respectively. ERG measurements would indicate that all three animals had 
very limited eyesight at 23 months of age. In contrast, treated animal 1165 lost retinal function at 
14.2 months, failed to traverse the maze at 19.4 months of age and also lost the most intracranial 
volume over its lifetime.  
The treated CLN6 animals also had varied responses to treatment. They performed better than 
the untreated CLN6-/- controls, but apart from one animal (1042) they did not respond as well as 
the CLN5 genotype. The CLN6 treated animals were euthanised with moderate or advanced 
disease between 18.2 and 22.3, in contrast to the CLN5 treated animals who were euthanised 
between 22.3 and >44 months. The CLN6 treated animals also lost more ICV volume than their 
CLN5 counterparts, between -5.9 and -10.6ml, versus +2.4ml to -4.2ml.  
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The maze data collected correlated well with the ICV volume loss, time to euthanasia, and ERG 
data collected on the sheep of both CLN5 and CLN6 genotypes. The treated animals would 
ultimately fail the maze, due to deteriorating eyesight. The treatments given were specifically 
brain directed and, whilst may protect against atrophy of the visual cortex of the brain, would not 
ameliorate the deterioration of the retina of the eye which confers blindness at around 12-16 
months of age. Thus loss of vision becomes a confounding factor, when using a visual based maze 
to gauge cognitive decline. This study intended to assess the suitability of a maze as an early 
measure of disease progression, before the loss of eyesight. Due to the length of time taken to 
arrive at the final conformation of the maze, it was decided to repeat the experiment, using the 
final more rigorous form of the maze developed in this study, in a younger cohort of animals. This 
additional study would investigate whether the final maze configuration was able to discriminate 
between a normal and affected animal at an earlier time than was achieved in this study. 
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3 Experiment 2 
3.1 Introduction 
Experiment 1 developed a more stringent maze that could distinguish between normal and 
affected animals CLN5-/- at 14 months and between normal and affected CLN6-/- at 11 months of 
age. This study used that final version of the maze at a younger starting point of 5.2 months of 
age. The hypothesis was that the more complex maze would allow earlier discrimination between 
normal and affected animals, and hence allow earlier monitoring of treatment efficacy. This study 
also introduced maze reversal learning as a comparatively more demanding task. This has been 
demonstrated in previous sheep maze studies (Hunter et al., 2015; Johnson et al., 2012; Morton 
& Avanzo, 2011). Morton and Avanzo used coloured buckets as visual stimuli, with one colour 
consistently contained the food reward, and all 7 animals reached an 80% correct choice criterion 
after 56 choices. When the colour of the bucket the reward was contained in was reversed the 
80% criterion was reached by all animals after 88 choices. The study by Johnson et al (2012) was 
based on spatial learning, and exposed sheep (n=12) to a T maze with a feed reward consistently 
on one side. After 9 exposures to this maze, all animals went to the correct side. The side of the 
food reward was then switched to the alternative side of the maze, and after 9 exposures to the 
change, 78% of animals went directly to the new site of the food reward. Therefore the capability 
of sheep to learn a reversal in stimuli or a spatial reversal has been established, and in this study 
the reversal was spatial, but reinforced with a learned visual stimuli. 
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3.2 Materials and methods 
3.2.1 Animals and experimental design 
This study was to evaluate the final configuration of the maze used in experiment 1, as a tool for 
assessing Batten disease progression. The study was carried out with CLN5+/- and CLN6+/- normal 
controls (n=3), and CLN5-/- and CLN6-/- affected controls (n=3). Three treated CLN5-/- cohorts were 
included; one treated by scAAV9.CLN5 at 3 months of age (n=6), another similarly treated at 6 
months (n=3) and a third cohort treated at 9 months (n=3). The CLN6-/- treatment group was 
treated by either scAAV9.CLN5 (n=3), or a combination of scAAV9.CLN5 and CLN6 (n=3) at 3 
months of age (Table 3-1).  
The animals were first tested at a mean age of 5.2 months (min 4.9, max 5.5 months), and were 
subjected to five consecutive runs through the maze. When the animals were 9.8, 11.3, 12.4 and 
14 months old they were additionally tested in a reverse maze. After the initial five runs the 
barrier gates were slid across to the opposite side and the maze was then reversed. The sheep 
were run through the reversed maze four times. Testing of all animals finished at 14 months old. 
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Sheep # Genotype Treatment Other in vivo assessments 
1002 CLN6+/- None, normal 
control 
 
None 
1004 CLN6+/- 
1006 CLN6+/- 
1100 CLN5+/- 
1106 CLN5+/- 
1116 CLN5+/- 
1027 CLN6-/-   
None, affected 
control 
CT, ERG 
1046 CLN6-/-   
1047 CLN6-/-   
1119 CLN5-/-   
1125 CLN5-/-   
1142 CLN5-/-   
1012 CLN6-/-   sc AAV9 CLN6@ 3 
months 
 
CT. ERG 
1020 CLN6-/-   
1030 CLN6-/-   
1014 CLN6-/-   sc AAV9 CLN5 and 
CLN6 @ 3 months 
1023 CLN6-/-   
1031 CLN6-/-   
1102 CLN5-/- 
sc AAV9 CLN5@ 3 
months 
 
1104 CLN5-/- 
1111 CLN5-/- 
1120 CLN5-/- 
1123 CLN5-/- 
1128 CLN5-/- 
1185 CLN5-/- sc AAV9 CLN5 @ 6 
months 
 CT. ERG 
1186 CLN5-/- 
1187 CLN5-/- 
1143 CLN5-/- sc AAV9 CLN5 @ 9 
months 
 
1163 CLN5-/- 
1165 CLN5-/- 
Table 3-1. List of animals used in Experiment 2. 
3.2.2 GPS tracking 
Animals were tracked with the same equipment, and in the same manner as described in 
Experiment 1.  
3.2.3 Maze 
The maze was the same as the final configuration of the maze described in Experiment 1.  
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3.2.4 Gene therapy 
The gene therapy procedure is described in experiment 1. The cohorts for this experiment are shown 
in Table 3-1. 
3.2.5 Statistical techniques 
Means and corresponding SEM was calculated for each group at each time point. Student’s t-
tests were performed to test each group against the normal controls at each time point. 
Differences were regarded as significant where P<0.05. Where individual treated and untreated 
affected animals were compared to the control group, they were considered to be significantly 
different from controls when they were more than 1.96 standard deviations away from normal 
control mean values. 
 
3.3 Results 
3.3.1 Heterozygous normal control animals  
Mean traverse times for heterozygous normal control sheep of each breed were compared 
(Figure 3-1). Times were only significantly different (P<0.05) for the CLN5+/- and CLN6+/- control 
groups at 6.4 and 9.7 months, when the CLN5+/- were slower than the CLN6+/-. The CLN5+/- and 
CLN6+/- cohorts were both significantly (P<0.05) slower on the first run through the maze than in 
all subsequent runs. 
34 
 
 
Figure 3-1. Mean (+/- sem) maze traverse times for normal CLN5+/- and CLN6+/- cohorts (n=3). 
Asterisk denotes significant difference (P<0.05). 
The ratio of distance travelled to the linear distance through the maze for both cohorts of normal 
control sheep were also plotted (Figure 3-2). There was no significant difference (P>0.05) at any 
times although, as in the time measurement, both genotypes travelled significantly (P<0.05) 
longer distances on their first exposure to the maze.  
3.3.2 Maze transit times for normal control and affected cohorts 
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Figure 3-2. Mean (+/- sem) ratio of distance travelled to linear distance 
through the maze for normal CLN5+/- and CLN6+/- cohorts (n=3). 
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Figure 3-3. Mean (+/- sem) maze traverse times for normal (blue line) and affected (red line) CLN5 
and CLN6 cohorts (n=3). Asterisk denote significant differences (P<0.05). 
The mean traverse times for CLN5-/- affected and CLN5+/- normal animals (Figure 3-3) showed that 
the affected cohort was only significantly (P<0.05) slower at three time points (8.8, 10 and 11.3 
months). The data for the CLN6 animals (Figure 3-3) showed that the CLN6-/- cohort was 
significantly (P<0.05) slower than the normal controls up until 11.3 months of age, and then again 
at 12 and 14 months of ages.  
3.3.3 Maze distance ratios for normal control and affected cohorts 
The distance travelled as a proportion of the linear distance was calculated for all four cohorts 
(Figure 3-4) and compared to the time results (Figure 3-3).There was much less variability in the 
distance data. The CLN5-/- affected sheep took a significantly (P<0.05) longer path than their 
normal CLN5+/- counterparts at most of the time points, and the mean distance covered by the 
normal cohort was always less than the affected cohort took. The CLN6-/- sheep took a 
significantly (P<0.05) longer path than the normal CLN6+/- sheep at the two earliest time points of 
5.2 and 7.4 months, but for the rest of the experiment there was no significant (P>0.05) 
difference between the cohorts.   
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Figure 3-4. Mean (+/- sem) ratios of distance travelled to linear distance through the maze for 
CLN5 and CLN6 normal (blue line) and affected (red line) cohorts (n=3). Asterisks denote 
significant differences (P<0.05). 
3.3.4 Maze transit times for the CLN5-/- treated cohort 
Maze transit times for the three CLN5-/- cohorts that received sc AAV9 CLN5 treatment at 3, 6 and 
9 months of age were plotted against the normal and untreated CLN5-/- sheep data. Results are 
presented in Figure 3-5 and Table 3-2. 
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Figure 3-5. Maze traverse times for individual CLN5-/- sheep treated by gene therapy at 3 
months (A), 6 months (B) or 9 months (C), plotted against mean times for normal (blue line) 
and affected (red line) controls.  
Sheep treated at 3 and 6 months traversed the maze in similar or faster times than the untreated 
affected controls at most time points. Treatment at 9 months resulted in more erratic traverse 
times. Two of the three animals treated at 9 months of age were typically slower than untreated 
affected sheep. However one 9-month treated animal (1163) was consistently as fast as normal 
controls at all times after its initial baseline run. Individual data for the untreated and treated 
CLN5-/- animals (Table 3-2) showed a random scattering of times that were significantly slower 
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(95% c.i.) than the normal control cohort throughout the course of the experiment. There was no 
trend of either the untreated or treated animals becoming significantly slower at the end of the 
14 months.  
Age (months) 
  5.2 6.4 7.4 8.8 9.8 11.3 12.4 14.0 
affected CLN5-/- 
1119 44.1 20.3 38.8 99.1 97.6 104.1 34.4 15.1 
1125 77.4 15.9 22.9 61.8 45.4 29.7 21.1 28.9 
1142 111.2 40.5 24.6 18.5 17.6 15.6 20.9 15.8 
Treated CLN5-/- (3mth) 
1102 55.2 24.9 24.5 30.1 11.7 15.9 17.4 19.4 
1104 35.6 64.8 99.9 46.3 35.6 24.3 21.8 23.6 
1111 70.0 24.6 65.2 49.8 21.4 33.8 30.0 31.7 
1120 45.8 31.1 35.9 47.4 22.4 22.3 19.5 81.8 
1123 94.8 21.7 20.3 19.4 19.1 20.4 12.4 21.7 
1128 55.3 16.5 22.8 29.6 21.3 19.7 22.4 37.9 
Treated CLN5-/- (6mth) 
1185   30.2 23.7 9.8 10.9 27.5 40.0 41.7 
1186   21.6 120.0 64.9 24.8 26.4 28.5 50.8 
1187   8.8 7.3 8.4 8.4 37.6 19.2 21.3 
Treated CLN5-/- (9mth) 
1143       120.0 110.7 44.8 19.9 71.5 
1163       91.6 27.5 17.3 16.8 21.4 
1165       34.1 56.6 34.4 88.6 26.2 
Table 3-2 Mean traverse times for individual CLN5-/- affected and CLN5-/- treated by gene therapy 
at 3, 6 and 9 months of age. Red figures indicate significantly slower (95% c.i.) than normal 
control cohort 
 
 
3.3.5 Maze distance ratios for the CLN5-/- treated cohort 
As before the ratio of distance travelled to linear distance for the CLN5-/- animals who received 
brain-directed sc AAV9 CLN5 treatment at 3, 6 or 9 months was plotted against the mean normal 
and untreated CLN5-/- sheep data (Figure 3-6).  
39 
Figure 3-6. Ratios of distances travelled to the linear distance through the maze for individual 
CLN5-/- sheep treated by gene therapy at 3 months (A), 6 months (B) or 9 months (C), plotted 
against mean times for normal (blue line)and affected (red line) controls. 
This showed that the apart from occasional individuals, the 3 and 6 month treated cohorts 
traversed the maze by a shorter route than the average untreated affected animals. Two of the 
three animals in the 9 month treated cohort frequently took a longer path then the affected 
control cohort, whilst animal (1163) was more direct. 
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Table 3-3. Mean individual ratios of distance travelled to linear distance through the maze, for 
CLN5-/- affected and CLN5-/- treated by gene therapy at 3, 6 or 9 months of age. Red figures 
indicate significantly slower (95% c.i.) than normal control cohort. nd = no data, due to failure of 
GPS unit. 
The individual data (Table 3-3) showed that the untreated CLN5-/- animals were frequently taking 
a longer path than the normal controls. Animals treated at 3 months rarely took a longer path, 
whilst the 6 month treated cohort began to take a longer path from 11.3 months. The 9 month 
treated sheep were nearly always taking a significantly (P<0.05) longer path than normal controls. 
3.3.6 Maze transit times of the CLN6-/- treated cohort  
Maze transit times for the CLN6-/- cohort that received sc AAV9 CLN5 or CLN6 treatment at 3 
months of age were plotted against the normal and untreated CLN5-/- sheep data in Figure 3-7and 
Table 3-4. There was considerable variation in times from individuals within the untreated 
affected cohort. One animal (1027) was always significantly (95% c.i.) slower than the normal 
controls, and failed to transit the maze at 12.4 months. Another (1047) was only significantly 
slower on two occasions in the middle of the study (8.8 and 9.8 months), and the third (1046) 
always traversed the maze at times equivalent to its normal counterparts.  
5.2 6.4 7.4 8.8 9.8 11.3 12.4 14.0
1119 5.08 1.61 1.81 2.46 3.85 2.69 nd 3.05
1125 3.21 1.55 1.58 2.76 1.89 1.61 nd 1.65
1142 11.58 2.46 2.00 2.09 1.56 1.97 nd 5.61
1102 4.12 1.45 1.71 1.51 1.53 1.62 nd 1.66
1104 2.92 2.37 1.79 2.11 1.62 1.56 1.58 1.55
1111 5.45 2.04 1.68 1.99 1.62 2.23 nd 2.02
1120 3.36 1.47 1.70 1.54 1.47 1.56 nd 2.13
1123 7.07 1.56 1.58 1.61 1.54 1.57 1.36 1.43
1128 4.35 1.65 1.62 2.03 nd 1.55 1.67 1.59
1185 2.07 1.73 1.34 1.37 1.79 nd 2.00
1186 1.57 2.59 1.98 1.55 1.71 1.80 1.73
1187 1.31 1.37 1.29 1.39 1.72 nd 1.57
1143 4.26 4.94 2.41 1.87 2.92
1163 6.64 2.32 1.81 1.73 nd
1165 2.03 nd 2.56 3.37 1.78
Treated CLN5-/- (3mth)
Treated CLN5-/-  (6mth)
Treated CLN5-/- (9mth)
affected CLN5-/-
Age (months)
41 
 
 
Figure 3-7. Maze traverse times for individual CLN6-/- sheep treated by gene therapy at 3 months, 
plotted against mean times for normal (blue line) and affected (red line) controls. 
Age (months) 
  5.2 6.4 7.4 8.8 9.8 11.3 12.4 14.0 
Affected CLN6-/- 
1027 120 52.6 81.4 89.7 89.8 33.9 120   
1046 55.8 20.1 25.6 17.1 16.8 21.6 16.4 25.7 
1047 93.2 10.8 19.0 71.1 53.1 12.2 38.4 13.7 
Treated CLN6-/- (3mth) 
1012 78.9 8.9 10.2 12.4 14.1 17.9 37.6 68.7 
1014 49.7 43.8 13.6 17.6 11.5 14.4 18.5 98.7 
1020 48.3 10.7 17.5 18.5 17.8 26.0 14.1 18.0 
1023 48.2 41.7 17.7 19.0 11.4 25.5 12.4 35.3 
1030 85.9 11.5 16.1 14.6 23.3 32.3 11.3 nd 
1031 87.0 6.7 9.5 30.5 79.8 61.3 21.7 15.0 
 
Table 3-4. Mean traverse times for individual CLN6-/- affected and CLN6-/- animals treated by gene 
therapy at 3 months of age. Red figures indicate significantly slower (95% c.i.) than normal control 
cohort. nd = no data. 
There were very few occurrences over the course of the experiment of the treated animals being 
significantly (95% c.i.) slower than the normal cohort. 
3.3.7  Maze distance ratio of the CLN6-/- treated cohort 
The ratio of distance travelled to linear distance for the CLN6-/- animals who received brain-
directed gene therapy at three months were plotted against the CLN6-/- affected and CLN6+/- 
normal controls (Figure 3-8). The individual data (Table 3-5) show that only one of the untreated 
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controls (1027) took a significantly (95% c.i.)  longer route than a normal animal. Treated animals 
travelled similar distances to the normal controls until towards the end of the experiment and at 
the last testing at 14 months four of the five treated animals travelled a significantly (95% c.i.) 
longer path through the maze.  
 
Figure 3-8. Ratio of distance travelled to linear distance through the maze for individual CLN6-/- 
sheep treated by gene therapy at 3 months of age, plotted against mean times for normal (blue 
line) and affected (red line) controls. 
Age (months 
  5.2 6.4 7.4 8.8 9.8 11.3 12.4 14.0 
Affected CLN6-/- 
1027 12.75 3.05 2.20 1.68 nd 2.10 nd F 
1046 3.61 1.40 nd 1.46 nd 1.47 1.62 1.37 
1047 6.90 1.50 1.58 1.87 1.28 1.48 nd 1.53 
Treated CLN6-/- (3 months) 
1012 5.80 1.42 1.43 1.47 1.62 nd nd 5.09 
1014 4.53 3.77 1.81 1.60 1.42 1.64 nd 6.14 
1020 3.81 1.39 1.37 1.57 1.51 1.76 1.65 1.45 
1023 3.66 1.93 1.51 1.34 1.41 2.30 nd 4.14 
1030 6.04 1.72 1.37 1.85 1.65 nd 1.60 nd 
1031 6.05 1.28 1.42 1.49 2.08 1.90 1.74 1.67 
Table 3-5. . Mean individual ratios of distance travelled to linear distance through the maze, for 
CLN6-/-affected and CLN6-/- animals treated by gene therapy at 3 months of age. Red figures 
indicate significantly slower (95% c.i.) than normal control cohort. nd = no data, due to failure of 
the GPS unit. 
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3.3.8 Reverse maze traverse times of normal and affected control cohorts 
There were no significant differences (P<0.05) in the times taken by the normal CLN5+/- and 
CLN6+/- cohorts at any time (data not shown). The normal and affected cohorts of both breeds 
were plotted against each other (Figure 3-9). Their ability to traverse the reversed maze was very 
variable, and the individual data (Table 3-6) show that over the time they were tested there was 
no tendency for the affected cohort to become slower as the disease progressed.
 
Figure 3-9. Mean (+/- sem) reverse maze traverse times for CLN5 and CLN6 normal (blue line) and 
affected (red line) cohorts. Asterisks denote significant difference (P<0.05). 
 
Age (months) 
  9.8 11.3 12.4 14.0 
CLN5-/- affected 
1119 120 120 51.7 28.2 
1125 98.8 44.1 20.3 26.7 
1142 36.7 19.1 25.6 19.4 
CLN6-/- affected 
1027 47.3 96.7 nd 120 
1046 27.1 20.0 20.2 33.5 
1047 40.7 32.0 24.0 49.5 
Table 3-6. Reverse maze traverse times for individual CLN5-/- and CLN6-/- affected animals. Red 
figures indicate significantly (95% c.i.) slower than normal control cohort. nd = no data. 
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3.3.9 Reverse maze distance ratios of  normal and affected control cohorts 
The distance travelled as a proportion of the linear distance was calculated for all four cohorts, 
and the affected means plotted against the means of the normal controls (Figure 3-10). The CLN5 
affected cohort took a significantly (P<0.05) longer path through the maze at 11.3 and 14 months 
of age.  Overall there was a trend for both CLN5 genotypes to reduce path length through the 
maze over time. 
Figure 3-10. Mean (+/- sem) ratios of distance travelled to linear distance through the reverse 
maze for CLN5 and CLN6 normal and affected cohorts. Asterisks denote significant differences 
(P<0.05). 
The CLN6-/- affected cohort took a significantly (P<0.05) longer path on their first time through 
the reverse maze, at 9.8 months, than the CLN6-/- controls. However there was no significant 
(P>0.05) difference between the affected and normal CLN6 cohorts when tested at the later ages 
(11.3, 12.4 or 14 months).  
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 Age (months)  
  9.8 11.3 12.4 14 
Tag #  CLN5
-/- affected 
1119 nd 2.25 nd 1.81 
1125 2.84 2.76 nd 1.65 
1142 2.58 2.57 nd 2.08 
                                      CLN6-/- affected  
1027 nd 2.57 unable  
1046 nd 1.37 1.58 1.46 
1047 2.89 1.61 nd 1.69 
Table 3-7. Mean ratios of distance travelled to linear distance through the reverse maze for 
individual CLN5-/- and CLN6-/- affected animals. Red figures indicate significantly (95% c.i.) slower 
than normal control cohort. nd = no data, due to failure of GPS unit. 
The individual data for the CLN5-/- affected control cohort (Table 3-7) showed that all three 
animals took a significantly (P<0.05) longer route than the normal controls at the 11.3 month 
testing. This was mostly attributable to normal control animals taking a shorter path at that time 
(Figure 3-10), and overall CLN5 affected animals got slightly better at following a more direct 
route over time. Data were only available for one of the CLN6 affected cohort (1047), at the first 
time point (9.8 months), and it took a significantly (95% c.i.) longer route through the maze than 
normal controls. The CLN6 affected animal, 1027, also took a significantly (95% c.i.) longer route 
at 11.3 months, and by 12.4 months was unable to traverse the maze. 
3.3.10 Reverse maze transit times of the CLN5-/- treated cohort  
Maze traverse times for the three CLN5-/- cohorts that received sc AAV9 CLN5 treatment at 3, 6 or 
9 months of age were plotted against the normal and untreated CLN5-/- sheep data. Results are 
presented in Figure 3-11. The six animals treated at 3 months recorded faster traverse times than 
the mean affected control cohort until final testing at 14 months of age. When 3 month treated 
individuals were compared to the normal cohort (Table 3-8) few were significantly slower over 
the duration of the experiment. Only treated animals 1104 and 1111 were significantly (95% c.i.) 
slower at 11.3 months and 1120 at 14 months. The 6 month treated cohort did not respond as 
46 
 
well to the reverse maze task as those treated at 3 months, with two of the three (1185 and 
1186) being significantly (95% c.i.) slower at 14 months of age.  
Figure 3-11. Reverse maze traverse times for individual CLN5-/- sheep treated by gene therapy at 3 
months (A), 6 months (B) or 9 months (C), plotted against mean times for normal (blue line) and 
affected (red line) controls. 
One of the 9 month treated cohort (1143) failed to traverse the reverse maze at 9.8 and 11.3 
months of age, and was significantly (95% c.i.) slower than the mean of the normal controls at 14 
months. Of the other two animals in the 9 month treated cohort, animal 1165  was significantly 
(95% c.i.) slower than the mean of the normal control cohort at both 11.3 and 14 months of age, 
whilst 1163 was as fast as a normal sheep at all times. 
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Age (months) 
  9.8 11.3 12.4 14.0 
CLN5-/- treated at 3 months 
1102 17.7 26.0 23.5 27.5 
1104 38.2 58.9 26.0 36.7 
1111 75.5 50.6 18.9 28.0 
1120 24.5 42.9 30.0 53.7 
1123 45.8 29.1 20.7 25.7 
1128 46.2 30.4 29.2 46.6 
CLN5-/- treated at 6 months 
1185 57.1 117.1 41.3 53.8 
1186 65.7 29.6 36.5 54.4 
1187 59.8 54.1 32.6 31.4 
CLN5-/- treated at 9 months 
1143 120 120 42.0 59.5 
1163 37.6 29.2 18.6 30.1 
1165 95.2 65.7 39.0 82.2 
Table 3-8. Reverse maze mean traverse times for individual CLN5-/- affected and CLN5-/- animals 
treated by gene therapy at 3, 6 or 9 months of age. Red figures indicate significantly slower 
traverses (95% c.i.) than normal control cohort. 
3.3.11 Reverse maze distance ratios for CLN5-/- treated cohorts 
The ratio of distance travelled to linear distance for the CLN5-/- animals who received brain-
directed sc AAV9 CLN5 treatment at 3, 6 or 9 months was plotted against the mean normal and 
untreated CLN5-/- sheep data Figure 3-12. As with the time data, the majority of the distance 
ratios for the animals treated at 3 and 6 months were shorter than for the affected control 
cohort. Again the 9 month treated data were more variable. Analysis of individual data (Table 
3-9), showed that all animals in the untreated affected and 9 month treated cohorts followed a 
significantly longer path at 11.3 months (than normal controls). This was likely due to better 
performance of normal controls at that time rather than deterioration of performance of the 
affected and treated animals. 
48 
 
 
Figure 3-12. Ratios of distance travelled to linear distance through reverse maze for individual 
CLN5-/-animals treated by gene therapy at 3 (A), 6 (B) or 9 (C) months of age, plotted against 
mean normal controls (blue line) and mean affected controls (red line). 
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Age (months) 
  9.8 11.3 12.4 14 
CLN5-/- affected  
  
CLN5-/- affected control 
  
  
1119 nd 2.25 nd 1.81 
1125 2.84 2.76 nd 1.65 
1142 2.58 2.57 nd 2.08 
CLN5-/- treated @ 3 mth  
  
CLN5-/- treated @ 3 mth 
  
  
1102 2.62 1.83 nd 2.13 
1104 2.21 2.64 1.75 1.93 
1111 2.89 2.14 nd 1.96 
1120 1.89 1.83 nd 1.89 
1123 3.26 1.51 1.74 2.18 
1128 2.01 1.73 1.88 1.66 
CLN5-/- treated @ 6 mth  
  
  
CLN5-/- treated @ 6 mth 
  
  
1185 1.67 3.20 nd 2.55 
1186 2.09 1.89 1.79 2.35 
1187 2.09 1.69 nd 1.77 
CLN5-/- treated @ 9 mth  
  
  
CLN5-/- treated @ 9 mth 
  
  
1143 nd 2.84 3.17 3.38 
1163 3.07 2.70 1.73 nd 
1165 nd 3.59 2.14 2.89 
Table 3-9. Ratios of distance travelled to linear distance through reverse maze for CLN5-/- affected 
and CLN5-/- animals treated at 3, 6 or 9 months of age. Red figures indicate significantly (P<0.05) 
longer paths then normal controls. nd = no data ( due to GPS unit failure). 
3.3.12 Reverse maze traverse times of the CLN6-/- treated cohort  
Reverse maze traverse times for the CLN6-/- cohort that received gene therapy at 3 months of age 
were plotted against the normal and untreated CLN6-/- sheep data. Results are presented in 
Figure 3-13 and Table 3-10. The treated cohort were slow for the initial maze runs at 9.8 months, 
with 5 of the six animals significantly (95% c.i.) slower than normal controls. After this there was 
only one treated animal (1014) that was significantly (95% c.i.) slower than the mean normal time 
at 14 months of age. 
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Figure 3-13. Reverse maze traverse times for individual CLN6-/- sheep treated by gene therapy at 3 
months, plotted against mean times for normal (blue line) and affected (red line) controls. 
Age (months) 
  9.8 11.3 12.4 14.0 
CLN6-/- affected 
1027 47.3 96.7 nd 120 
1046 27.1 20.0 20.2 33.5 
1047 40.7 32.0 24.0 49.5 
CLN6-/- treated at 3 months 
1012 38.0 22.7 48.4 39.3 
1014 37.4 17.8 45.1 109.3 
1020 70.8 15.9 18.4 39.2 
1023 20.6 17.9 17.1 19.3 
1030 47.3 39.7 14.3   
1031 78.3 24.7 14.6 21.9 
Table 3-10. Reverse maze mean traverse times for individual CLN6-/- affected and CLN6-/- animals 
treated by gene therapy at 3 months of age. Red figures indicate significantly slower traverses 
(95% c.i.) than those of the normal cohort. 
3.3.13 Reverse maze distance ratios for CLN6-/- treated cohorts 
The ratio of distance travelled to linear distance for the CLN6-/- animals who received brain-
directed gene therapy at three months were plotted against the untreated CLN6-/- affected and 
CLN6+/- normal controls (Figure 3-14). The individual data Table 3-11 showed the untreated 
control (1047) and four of the six treated animals were significantly (95% c.i.) slower than the 
normal sheep on their first attempt at the reverse maze. When last tested at 14 months, one of 
the untreated cohort (1027) could no longer transit the maze, and another (1047) took 
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significantly (95% c.i.)  longer route than the normal cohort. Similarly the same four out of five of 
the treated cohort were taking a significantly (95% c.i.) longer route at this time. Only treated 
animal 1023 remained on a similar path length to normal animals. 
 
Figure 3-14. Ratio of distance travelled to linear distance through reverse maze for individual 
CLN6-/- sheep treated by gene therapy at 3 months, plotted against mean times for normal (blue 
line) and affected (red line) controls. 
 
Age (months) 
  9.8 11.3 12.4 14 
CLN6-/- affected control 
1027 no data 2.57 unable unable 
1046 no data 1.37 1.58 1.46 
1047 2.89 1.61 no data 1.69 
CLN6-/- treated at 3 mth 
1012 2.62 no data  no data 1.73 
1014 2.21 1.52 no data 4.98 
1020 2.89 1.69 1.83 1.67 
1023 1.89 1.92 no data 1.65 
1030 3.26 no data  1.57 no data 
1031 2.01 1.52 1.74 1.83 
Table 3-11. Ratios of distances travelled to linear distance through reverse maze for individual 
CLN6-/- sheep and CLN6-/- sheep treated by gene therapy at 3 months. Red figures indicate 
significantly differences (95% c.i.) to the normal cohort.  
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3.3.14 Data summary for CLN5-/- untreated and treated cohorts 
The ERG, ICV and clinical outcome for the CLN5-/- untreated and treated animals is summarised in 
Table 3-12.  
Sheep Genotype Treatment 
Minimal 
ERG 
(months) 
ICV 
changes 
over time 
Clinical outcome 
1119 CLN5-/- None n.t n.t 
Euthanised at 16.4 m, blind, 
advanced disease 
1125 CLN5-/- None n.t n.t 
Euthanised at 16.3 m, blind, 
advanced disease 
1142 CLN5-/- None n.t n.t 
Euthanised at 16.2 m, blind, 
advanced disease 
1102 CLN5-/- 
scAAV9.CLN5 
at 3 m (LD) 
25 
+12.5 mL 
(3 – 31 m) 
Alive at 31 m, blind, no other 
disease symptoms 
1104 CLN5-/- 
scAAV9.CLN5 
at 3 m (HD) 
19.8 
-2.5 mL 
(3 – 27 m) 
Euthanised at 27.4 m, blind, 
moderate clinical disease 
1111 CLN5-/- 
scAAV9.CLN5 
at 3 m (LD) 
18.8 
+3.1 mL 
(3 – 31 m) 
Alive at 31 m, blind, no other 
disease symptoms 
1120 CLN5-/- 
scAAV9.CLN5 
at 3 m (HD) 
18.8 
+9.6 mL 
(3 – 31 m) 
Alive at 31 m, blind, no other 
disease symptoms 
1123 CLN5-/- 
scAAV9.CLN5 
at 3 m (HD) 
18.8 
+5.0 mL 
(3 – 31 m) 
Alive at 31 m, blind, no other 
disease symptoms 
1128 CLN5-/- 
scAAV9.CLN5 
at 3 m (LD) 
18.7 
+9.6 mL 
(3 – 31 m) 
Alive at 31 m, blind, no other 
disease symptoms 
1185 CLN5-/- 
scAAV9.CLN5 
at 6 m (HD) 
18.1 
-5.3 mL 
(3 – 21 m) 
Euthanised at 21.3 m, blind, 
moderate clinical disease 
1186 CLN5-/- 
scAAV9.CLN5 
at 6 m (HD) 
18.1 
-1.1 mL 
(3 – 31 m) 
Alive at 31 m, blind, no other 
disease symptoms 
1187 CLN5-/- 
scAAV9.CLN5 
at 6 m (HD) 
18.1 
-0.4 mL 
(3 – 31 m) 
Alive at 31 m, blind, no other 
disease symptoms 
1143 CLN5-/- 
scAAV9.CLN5 
at 9 m (HD) 
18.6 
-6.4 mL 
(3 – 18 m) 
Euthanised at 18.5 m, blind, 
advanced disease 
1163 CLN5-/- 
scAAV9.CLN5 
at 9 m (HD) 
18.4 
+4.4 mL 
(3 – 31 m) 
Euthanised at 30.7 m, blind, 
moderate clinical disease  
1165 CLN5-/- 
scAAV9.CLN5 
at 9 m (HD) 
19.5 
-7.4 mL 
(3 – 21 m) 
Euthanised at 21.6 m, blind, 
moderate clinical disease  
Table 3-12. Data summary of ERG, ICV and clinical data collected on individual CLN5 animals. 
Abbreviations: n.t, not tested; LD, low dose 1.65x1012 vg; HD, high dose 5x1012 vg; vg, viral 
genomes; m, months. 
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The untreated affected cohort were all euthanized at just over 16 months with advanced disease. 
The treated cohorts had better outcomes, evident with all of the efficacy measures, and better 
the earlier they were treated which allowed extension of times to euthanasia. Five of the six 
animals that were treated at three months, and 2/3 of the animals treated at 6 months were still 
alive at 31 months, and apart from blindness were showing no other symptoms. The cohort 
treated at 9 months had the poorer outcomes, although one animal survived to 21.6 months and 
another to 30.7 months, considerably longer than the untreated cohort. Treatment did not 
improve ERG loss, all other animals losing ERG response at 18-19 months, although one of the 3-
month treated cohort (1102) retained an ERG response until 25 months. The ERG, ICV and clinical 
outcome for the CLN6-/- untreated and treated animals is summarised in Table 3-13. 
3.3.15 Data summary for CLN6-/- untreated and treated cohorts 
Sheep Genotype Treatment Minimal 
ERG 
(months) 
ICV 
changes 
over time 
Clinical outcome 
1027 CLN6-/- none n.t. n.t. Euthanised at 16.4 m, blind, 
advanced disease 
1046 CLN6-/- none n.t. n.t. Euthanised at 16.1 m, blind, 
advanced disease 
1047 CLN6-/- none n.t. n.t. Euthanised at 16.1 m, blind, 
advanced disease 
1012 CLN6-/- scAAV9.CLN5 
at 3 m (LD) 
16.5 -0.5 mL 
(3 – 17 m) 
Euthanised at 19.5 m, advanced 
disease 
1014 CLN6-/- scAAV9.CLN5/6 
at 3 m (HD) 
11.2 -4.8 mL 
(3 – 17 m) 
Euthanised at 19.0 m, advanced 
disease 
1020 CLN6-/- scAAV9.CLN5 
at 3 m (LD) 
18.1 -10.0 mL 
(3 – 17 m) 
Euthanised at 19.5 m, advanced 
disease 
1023 CLN6-/- scAAV9.CLN5/6 
at 3 m (HD) 
19.0 -7.1 mL 
(3 – 17 m) 
Euthanised at 18.9 m, advanced 
disease 
1030 CLN6-/- scAAV9.CLN5 
at 3 m (HD) 
17.9 -3.6 mL 
(3 – 17 m) 
Euthanised at 22.1 m, advanced 
disease 
1031 CLN6-/- scAAV9.CLN5/6 
at 3 m (LD) 
18.8 -6.8 mL 
(3 – 17 m) 
Euthanised at 22.1 m, advanced 
disease 
Table 3-13. Summary of the ERG, ICV and clinical data collected on individual CLN6 animals. 
Abbreviations: n.t, not tested; LD, low dose 1.65x1012 vg; HD, high dose 5x1012 vg; vg, viral 
genomes 
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The untreated affected cohort were all euthanized at 16.1 – 16.4 months with advanced disease. 
Treatment did not prevent the disease, with all treated animals ultimately succumbing, but likely 
delayed its onset, progression, and extended the lifespan of the animals in this study by 2-4 
months. There was minimal ICV loss in one animal (1012) compared to a previous study (K. 
Russell, 2017) which found an average of 5.8 ml loss between 3- 17m in untreated CLN6-/- 
animals. 
3.4  Discussion 
This study established that sheep were able to navigate the more complex maze that had been 
developed in Experiment 1. Three key trends were apparent. Firstly, the CLN5 Borderdales were 
often slightly slower than the CLN6 South Hampshires, but when using the ratio of the distance 
travelled through the maze to the linear distance, the performance of the normal cohort of both 
breeds was the same. Secondly, all animals were slowest and took their longest paths when first 
exposed to the maze, but were faster and took shorter paths in subsequent transits. This would 
appear to show the learning, and memory described in many other studies with sheep in mazes 
(C.V. Bazely D.R. Ensor, 1989; Camm et al., 2000; Hunter et al., 2015; Johnson et al., 2012; 
McBride et al., 2016; Morton & Avanzo, 2011). Finally, the untreated affected cohorts of both 
genotypes were generally slower and took a longer path length through the maze than their 
unaffected counterparts. Due to the variability between animals, and the small numbers (n=3) in 
the cohorts, this often did not reach significance. However the loss of ability of individual affected 
(both untreated and treated) animals to negotiate the maze correlated well with other measures 
of disease progression, from other concurrent studies on the same animals (Tables 3-12 and 3-
13). 
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3.4.1 CLN5 genotype 
The Borderdale sheep is a breed that appears to habituate to human contact quite readily (Erhard 
et al., 2006). In this study, where escape from the operator is one of the drivers to negotiate the 
maze, the readiness of Borderdale sheep to stop when about 10 metres from the operator was 
very apparent, and has been noted by other researchers working with this breed (McBride et al., 
2016). This means that the time taken to negotiate the maze is not a good measure of ability for 
these animals, as the data is very variable, and in this study although the untreated CLN5 affected 
controls appeared to be generally slower than the normal CLN5 cohort through both the normal 
and reversed maze, they were rarely significantly slower.  The path length is a more informative 
measure evident in the fact that the CLN5 affected cohort always took a longer path than the 
normal controls, reaching significance (P<0.05) at five of the eight time points, and significance at 
P<0.1 at the other times. When the maze was reversed the paths of the affected cohort were also 
significantly (P<0.05) longer at the final two times of 11.3 and 14 months.  
The time taken for the treated CLN5 Borderdale cohorts to transit the maze were quite variable. 
However conclusions could still be drawn on the validity of maze testing in the assessment of 
efficacy for the gene therapy trials. The CLN5-/- treated at 3 months of age responded well to 
treatment and performed well in both forms of the maze, and by both measures. There are 
occasions where individual animals would be significantly slower, or take a significantly longer 
path than the normal controls, but these were seldom, and randomly scattered over the 
experiment. There was no indication that the animals were deteriorating over the course of the 
study. The efficacy of the treatment was also reflected in the other measures of disease 
progression, such as ICV and the oBDRS. The majority (5/6) of this cohort were still alive at 31 
months, as opposed to the untreated CLN5-/- cohort who were euthanised at 16 months with 
advanced disease. The animals treated at 6 months also responded well to treatment, with two 
still alive at 31 months with no symptoms other than blindness. The animal (1185) that lost most 
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ICV and was euthanised at 21 months with moderate disease, performed as well as the other two 
in the cohort in the normal maze, but not as well in the reversed maze. Later treatment was not 
as effective and the performance of the cohort treated at 9 months was mixed. Animal 1143 lost 
ICV and was euthanised with advanced disease at 18.5 months. This animal was the poorest 
performer in the 9 month treated cohort in both configurations of the maze. The maze 
performance of the other two animals in the cohort was inconsistent. Animal 1163 performed 
well when time was used as a measure in both the normal and reversed mazes, and clinically by 
the ICV and longevity, but the distance ratios for this animal were consistently longer than those 
of the normal controls. The final animal 1165 performed better than 1143 but not as well as 
1163, and this was reflected in the clinical data for the animal. Overall the maze data were a good 
reflection of the variable response to treatment by this group.  
3.4.2 CLN6 genotype 
As was found in Experiment 1, time was a good measure of CLN6 South Hampshire’s ability in the 
maze. The South Hampshire breed does not appear to acclimate to the human contact as quickly 
as the Borderdales, and retained the desire to get away from the operator, and be reunited with 
their conspecifics.  The affected CLN6 cohort was significantly (P<0.05) slower than controls for all 
but one of the times between 5.2 and 14 months. The one time (12.4 months), where the mean 
of the affected cohort was not slower than the normal controls (Figure 3-7), was when the 
affected animal 1027 which normally struggled to transit the maze is missing from the data. 
Hence the CLN6-/- affected cohort was skewed by this animal. It was consistently significantly 
(P<0.05) slower than the normal controls throughout the whole of the study, and also much 
slower than the rest of the CLN6-/- affected cohort. The distance ratio showed the CLN6-/- affected 
cohort took a significantly (P<0.05) longer route at first exposure to the maze (5.2 months), and 
then again at 7.4 months, but ratios for the rest of the study were very similar for both the 
normal and reversed maze. 
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It can be seen from the clinical data that the CLN6 treatment was not as successful as treatment 
for the CLN5. This was not reflected in the times taken to transit the maze, although the treated 
cohort did perform particularly poorly when exposed to the reverse maze for the first time. Five 
of the six in the treatment group took a significantly longer time to negotiate the maze at the first 
exposure. The results for distance travelled show that 4 out of 5 animals were taking a 
significantly longer path for both the normal and the reversed maze when last tested at 14 
months.    
Overall this experiment did not achieve the objective of being able to discern the onset of Batten 
disease at an early stage. The fact that all the affected animals of both genotypes performed less 
well than normal animals when first exposed to the maze in either configuration formed the basis 
for the next experiment. It was decided to use a maze that was more biased to the executive 
function of sheep, rather than spatial learning. 
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4 Experiment 3 
4.1 Introduction 
The two-choice Y or T type maze for testing spatial learning and ability to associate visual cues 
with correct paths, or food rewards, has been widely used with sheep. Mazes without visual cues 
have been used to test the sheep’s ability to learn a path through a maze, generally with a food 
reward. Some of these studies have been proof of concept studies to test learning ability (Hunter 
et al., 2015; Johnson et al., 2012). The effects of prenatal undernutrition (Erhard et al., 2004; 
Hernandez et al., 2009), litter size and sex (Hernandez et al., 2009), age (Johnson et al., 2012) and 
experience (Hunter et al., 2015) have all been tested on the ability of sheep to learn a path. It has 
been known for some time that sheep are able to recognise a variety of visual cues. The ability to 
associate the visual cue of different commonly encountered plant types with a preferred type of 
feed pellet has been  shown (Edwards et al., 1997). Sheep are able  to discriminate colour 
brightness and hue (C.V. Bazely D.R. Ensor, 1989) and recognise other individual sheep of their 
own breed (Kendrick et al., 1995), although this ability was very variable between sheep breeds. 
Sheep have also been trained to associate pictures of a particular 3 month old lamb with a food 
reward, and then transfer that knowledge to pictures of the same lamb at one month of age 
(Ferreira et al., 2004). Furthermore this has been shown to be remembered in many animals up 
to 2 years later (Keith et al., 2001). The effects of prenatal undernutrition have also been studied 
with a T –maze (Camm et al., 2000) with the maternal ewe as the visual cue. The ability to visually 
discriminate between symbols in a maze has also been demonstrated (McBride et al., 2016; 
Morton & Avanzo, 2011). Once trained to associate a symbol or colour with a food reward, sheep 
were also able to learn a reversal of this association (Johnson et al., 2012; McBride et al., 2016; 
Morton & Avanzo, 2011).  
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In light of these studies it was decided to trial an adaptation of symbol recognition and reversal 
learning with the Batten disease affected animals in an attempt to be able to discriminate 
between the diseased and healthy unaffected states at an earlier time than was achieved with 
the field maze. 
4.2 Materials and methods 
The learning maze was set up in the same area as the previous maze, and occupied the same 
dimensions. It had three gates, and at each one the animal was presented with a choice of two 
alternative routes around the gate (Figure 3-15). Only one side was open to allow the animal 
passage through the maze, and this side was always associated with a green coloured feed bin 
and a large plus (+) symbol on a piece of (700 x 900mm) sized corflute plastic (Figure 3-16). The 
other side of the gate was blocked off and was always associated with a yellow feed bin and a 
triangular () symbol on a large plastic sign. 
 
Figure 3-15. Layout of learning maze. 
The animals had been habituated to the green bin and plus sign being associated with food, by 
regularly feeding of lucerne pellets (Farmlands Nutrition, P O Box 31, Rolleston New Zealand) to 
them in green bins associated with + signs in the field. The yellow bins and triangular signs were 
always associated with no food. The animals were followed through the maze by the operator, 
and were gauged to have completed a particular configuration of the maze when they made 
Start 
pen Feed 
bins 
Return race 
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three consecutive traverses without an error. Errors occurred when the animal entered the 
blocked off race indicated by the yellow feed bin. If the animal entered the error race, a plastic 
bag on a stick was waved at the animal as it exited. The animals were scored on the number of 
runs required before it had completed 3 consecutive error free runs, and the maximum score was 
24 runs. If the animal had completed 24 runs with a particular configuration without 3 
consecutive error free runs, then it was moved on to the next configuration. 
 
Figure 3-16. Photo of two choice learning maze, showing green bins and + signs associated with 
the correct course through the maze. 
When an animal was tested, it was run through the maze in four different configurations, always 
in the same order. The maze was initially run as a zig-zag with the “correct” path starting to right 
of first gate (Figure 3-15). When the animal had completed that set-up the maze was reversed to 
be a zig-zag with the correct path starting to the right. Then it was changed so that the correct 
path was to the right of all gates, then reversed so it was to the left of all gates. 
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4.2.1 Sheep 
Four groups of three animals were tested. The groups were CLN5+/- normal (n=3), CLN5-/- affected 
(n=3), CLN6+/- normal (n=3) and CLN6-/- affected (n=3). The animals were tested twice at an 
average age of 5.3 (min 5.1, max 5.7) and 6.4 months (min 6.2, max 6.8). 
4.2.2 Statistical techniques 
Means and corresponding SEM was calculated for each group at each time point. Student’s t-
tests were performed to test each group against the normal controls at each time point. 
Differences were regarded as significant where P<0.05. Where individual treated and untreated 
affected animals were compared to the control group, they were considered to be significantly 
different from controls when they were more than 1.96 standard deviations away from normal 
control mean values. 
 
4.3 Results 
The mean number of runs required by each cohort to complete all four variants of the maze was 
calculated and the values for the normal controls (heterozygotes; +/-) plotted against the affected 
controls (homozygous recessive; -/-). The CLN5-/- and CLN6-/- affected controls took significantly 
(P<0.05) more runs to complete all four maze variants at 6.4 months of age, but not at 5.3 
months (Figure 3-17). 
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Figure 3-17. Mean (+/- sem) number of runs for both CLN5 and CLN6 cohorts required to complete 
all four variants of the maze. Asterisk denotes significantly (P<0.05) different values. 
The number of runs required for each individual to complete each variant of the maze was 
plotted. There was no significant difference (p<0.05) between the means of the normal and 
affected cohorts for either genotype for any configuration of the maze at any time, and individual 
data were highly variable (Figure 3-18). 
 
 
  Age     Age 
CLN5+/- 5.3 6.4   CLN6+/- 5.3 6.4 
1104 37 39  1003 34 18 
1116 41 41  1005 40 25 
1164 36 21  1009 40 21 
mean 38 33.7   mean 38 21.3 
       
CLN5-/-       CLN6-/-     
1146 20 53  1045 39 34 
1147 25 45  1048 55 35 
1149 43 47  1049 32 28 
mean 29.3 48.3   mean 42 32.3 
 
Table 3-14 Total number of runs required to negotiate all 4 configurations of the maze for 
individual sheep. Red figures denote totals for affected sheep that are significantly (95% c.i.) 
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slower than the normal control cohort.
 
Figure 3-18. Number of runs required to get three consecutive error free runs, for individual 
normal (blue lines) and affected (red lines) animals of both genotypes at 5.3 and 6.4 of age. 
The affected individuals of both genotypes were compared with the normal control cohorts ( 
Table 3-15) and the number of times the individuals required significantly more attempts 
recorded. The CLN5-/- affected cohort only required significantly more runs on one occasion when 
5.3 months and three occasions when 6.4 months of age. The CLN6-/- affected cohort took more 
runs on four occasions at 5.3 months, and three at 6.4 months. There was no obvious pattern on 
which configuration the affected animals found more difficult than the normal cohort. 
 
 
 
 
5.3 months of age 6.4 months of age 
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  maze configuration 
  Zig zag Rev zig zag Side rev side Zig zag Rev zig zag Side rev side 
CLN5-/- affected 
1146 3 6 6 5 13 15 6 19 
1147 3 10 6 6 19 15 5 6 
1149 5 24 3 11 19 18 4 6 
CLN6-/- affected 
1045 13 15 6 5 5 19 6 4 
1048 23 19 4 9 14 9 6 6 
1049 8 4 15 5 5 11 4 8 
 
Table 3-15. The number of runs required for individual affected animals to complete 3 error free 
runs, for each configuration of the maze. Red figures indicate that affected animals required 
significantly (P<0.05) more runs than normal controls. 
4.4 Discussion 
This two-choice maze test was only run at two time points (5.3 and 6.4 months) at an early stage 
in the progression of the disease. These earlier time points were used as the aim of this more 
cognitively complex maze, was to discriminate between a normal or affected animal earlier than 
the two previous mazes. The two-choice maze demonstrated that at 6.4 months of age the 
affected cohorts of both genotypes took significantly more runs to complete all conformations of 
the maze than the normal control cohorts.  
All affected individuals of both genotypes also took more runs to complete all conformation than 
the normal controls at 6.4 months, but due to the variability of the normal control groups, the 
extra runs required by the individual CLN5-/- did not reach significance, and only reached 
significance with two of the three CLN6-/-. However, there was no pattern in the different 
individual conformations that the affected animals found more difficult to negotiate, and none of 
the affected animals consistently took significantly more runs through the various maze 
conformations. 
The animals used in this experiment were quite young, and this may have had a bearing on their 
ability in the maze. Previous published two-choice maze studies have been on sheep of various 
65 
 
ages, including 4 months (Hernandez et al., 2009), 6 months (Doyle et al., 2014), 11-18 months 
(Taylor et al., 2010),  12 months  (Morton & Avanzo, 2011), eighteen months (Erhard et al., 2004; 
Hernandez et al., 2009), 24 months (Lee et al., 2006), 24-36 months (McBride et al., 2016) and 
over 36 months of age (Ferreira et al., 2004; Peirce et al., 2001). Previously researchers  have 
found that 3.5 month old lambs performed markedly better than 2.5 month old lambs in a non-
matching-to–place, position habit and position habit reversal tasks, and remarked that the age at 
which performance is optimised has to yet be determined (Johnson et al., 2012). However 
(Hunter et al., 2015) found no significant difference between naive animals of 4.5 or 10 months 
of age for the majority of their maze learning and reversal tasks, and in fact 10 month old naive 
females were slower to work out the first reversal of the maze.  
The cumulative stress on the animals in this experiment, caused by naivety (this being their first 
exposure to a maze), getting stuck or the negative reinforcement of the waved plastic bag may 
also have affected the animals’ abilities. A study by (Doyle et al., 2014) found that exposure to a 
dog, accompanied by barking, caused sheep to make marginally significantly (P=0.057) more 
errors when traversing the maze on the first occasion, but not when subsequently exposed to the 
same stressor. Another study on the effects of prenatal undernutrition, found that lambs born to 
ewes that had undergone restricted nutrition, were more emotionally reactive and had stronger 
reactions to adverse events(Erhard et al., 2004). These animals were also slower to learn 
reversals of the maze. Whilst the effects were not dramatic in either of these studies, the 
potential of stress to influence the sheep’s ability should be taken into account when designing a 
testing protocol. 
Many of the previous studies involving sheep in mazes have included habituation and training 
periods prior to the experiment. As an example, the study by (Johnson et al., 2012) on T-maze 
learning in 3.5 month old lambs, involved an acclimatization of 15 exposures to the maze where 
the animals were fed inside the maze. This was followed by a training period of 45 runs through 
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the maze to food rewards. These animals had also been housed inside, and fed twice a day by the 
handlers. The current trial probably most resembles that carried one that also involved sheep 
following a path through a two-choice maze with the correct path indicated by symbols or 
colours (Morton & Avanzo, 2011). In that trial the sheep were habituated to human handling over 
a period of 4 months, and then to the maze by five 5-10 minute exposures on five separate 
occasions. The 7 animals then required 56 discriminations to reach a criterion of 80% correct in 
16 discriminations (12 correct choices in 16 attempts). When the colour was reversed the number 
of discriminations required to reach the criterion increased to 88, and the time required to put 8 
sheep through those two mazes was 9 days, as time to negotiate was not a parameter. The study 
by Morton and Avanzo (2011) was a ‘proof of concept’ and hence used normal sheep, and 
required a huge investment of time. Studies involving animals that have any form of hindrance to 
their ability (e.g. Batten disease affected sheep) could be expected to take longer to complete the 
studies. The current study included a period of acclimatisation to the green bin containing food 
within the field, and being associated with the + symbol, but this was not geographically in the 
context of the maze.  
 
 
 
 
 
 
5 Final conclusions 
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The mazes used in this study were able to discern the onset and progression of Batten disease, 
and maze failure correlated with other in vivo measures of disease progression already in use. 
The difference in temperament between the two breeds used in this study meant that recording 
both the time taken, and the distance covered compensated for these differences. Time being a 
good measure for the South Hampshire breed, with the more ‘flighty’ disposition, whereas the 
distance covered was a better measure for the Borderdale, with its more placid and equable 
nature. Successful gene therapy treatment was reflected in improved maze performance, but as 
the treatment did not include the eyes, the animals ultimately failed the maze due to loss of 
eyesight. However none of the maze tests utilised were able to detect disease onset any earlier 
than the methods currently in use. Despite not being able to assist in early disease diagnoses, 
maze testing was a useful adjunct method to assess efficacy in sheep who had received CLN5 or 
CLN6 gene therapy. 
Much of the published work with sheep and mazes have been proof-of-concept studies using 
normal animals. In many of these studies there has been a selection of animals, so animals 
unable to complete the task have been excluded. As an example, in a similar two-choice maze 
using visual discrimination of symbols only 64% (9/15 animals) of the Borderdale sheep 
completed the study (McBride et al., 2016). Another study looking at recognition of faces and 
symbols  found that many animals were unable to make the discrimination, and also found large 
breed differences, with one breed much more capable than the other(Kendrick et al., 1995). This 
infers that there is a large amount of variability in the ability of sheep to learn and negotiate 
mazes, which has been reinforced in this study. This individual variability when using cohorts of 
three animals, as in the current study, mean that statistical significance is hard to achieve. There 
also appears to be a large amount of variability within animals over time, which also makes 
interpretation of results difficult. 
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Many of the cognitively more difficult tasks that researchers have used require large amounts of 
time devoted to habituation, training and selection of animals capable of the task. The amount of 
time required was beyond the scope of this study, and selection of animals post treatment but 
these more cognitively demanding tasks may still have potential as a method of early diagnosis in 
ovine Batten disease, if the man hours required are available. 
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